Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
2 reports, 1 independent
Updated Oct 23
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Gilead Sciences
American company
Related events
- BioNTech announced new partnerships with Genmab, Pfizer, Bristol-Myers Squibb, and Genentech.
- Pfizer and Nexentis Technologies, both healthcare companies, are competing for investment, with Pfizer reporting higher revenue and earnings.
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- Pfizer and AT&T are discussed as blue-chip stocks as of June 30, 2026.
- AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.